ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

31 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

23 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

22 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

15 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

31 7 2023 06:52:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

26 7 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

21 6 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

30 5 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

19 5 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

10 5 2023 06:25:00 提供 Nasdaq GlobeNewswire

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

10 5 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

26 4 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

04 4 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

16 3 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

14 3 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

08 3 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

16 2 2023 15:44:36 提供 Nasdaq GlobeNewswire

Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

30 1 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

25 1 2023 06:25:00 提供 Nasdaq GlobeNewswire